19 June 2026
19 June 2026
By incorporating nonclinical testing services, the partnership seeks to standardise testing protocols across organisations.
The trial is studying ateganosine followed by cemiplimab in NSCLC patients resistant to checkpoint inhibitors and chemotherapy.
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
The study will enrol up to 40 participants across a maximum of five clinical sites in the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
